Display options
Share it on

Antimicrob Agents Chemother. 2009 Mar;53(3):1149-56. doi: 10.1128/AAC.01279-08. Epub 2008 Nov 24.

In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.

Antimicrobial agents and chemotherapy

Bharat D Damle, James A Dowell, Robert L Walsky, Gregory L Weber, Martin Stogniew, Philip B Inskeep

Affiliations

  1. Pfizer Inc, New York, New York, USA.

PMID: 19029327 PMCID: PMC2650573 DOI: 10.1128/AAC.01279-08

Abstract

Anidulafungin is a novel semisynthetic echinocandin with potent activity against Candida (including azole-resistant isolates) and Aspergillus spp. and is used for serious systemic fungal infections. The purpose of these studies was to characterize the clearance mechanism and potential for drug interactions of anidulafungin. Experiments included in vitro degradation of anidulafungin in buffer and human plasma, a bioassay for antifungal activity, in vitro human cytochrome P450 inhibition studies, in vitro incubation with rat and human hepatocytes, and mass balance studies in rats and humans. Clearance of anidulafungin appeared to be primarily due to slow chemical degradation, with no evidence of hepatic-mediated metabolism (phase 1 or 2). Under physiological conditions, further degradation of the primary degradant appears to take place. The primary degradation product does not retain antifungal activity. Anidulafungin was not an inhibitor of cytochrome P450 enzymes commonly involved in drug metabolism. Mass balance studies showed that anidulafungin was eliminated in the feces predominantly as degradation products, with only a small fraction (10%) eliminated as unchanged drug; fecal elimination likely occurred via biliary excretion. Only negligible renal involvement in the drug's elimination was observed. In conclusion, the primary biotransformation of anidulafungin is mediated by slow chemical degradation, with no evidence for hepatic enzymatic metabolism or renal elimination.

References

  1. J Clin Pharmacol. 2007 Mar;47(3):305-14 - PubMed
  2. Crit Rev Toxicol. 1992;22(1):1-21 - PubMed
  3. J Pharmacokinet Biopharm. 1996 Oct;24(5):461-73 - PubMed
  4. Antimicrob Agents Chemother. 2003 Oct;47(10):3149-54 - PubMed
  5. J Clin Pharmacol. 2005 Oct;45(10):1145-52 - PubMed
  6. J Pharmacol Exp Ther. 1993 Apr;265(1):401-7 - PubMed
  7. Expert Rev Anti Infect Ther. 2004 Aug;2(4):499-508 - PubMed
  8. Toxicol Pathol. 1995 Mar-Apr;23(2):199-208 - PubMed
  9. Antimicrob Agents Chemother. 2004 Apr;48(4):1272-80 - PubMed
  10. Drug Metab Dispos. 2004 Jun;32(6):647-60 - PubMed
  11. Mol Pharmacol. 1989 Jul;36(1):89-96 - PubMed
  12. J Clin Pharmacol. 2005 Dec;45(12):1373-82 - PubMed
  13. Drug Metab Dispos. 2005 Mar;33(3):413-8 - PubMed
  14. Diagn Microbiol Infect Dis. 2003 Feb;45(2):131-5 - PubMed
  15. Anal Biochem. 1987 Apr;162(1):24-32 - PubMed
  16. J Biol Chem. 1974 Oct 10;249(19):6302-10 - PubMed
  17. Antimicrob Agents Chemother. 2008 Jul;52(7):2673-6 - PubMed
  18. Drug Metab Dispos. 2000 Nov;28(11):1274-8 - PubMed
  19. Antimicrob Agents Chemother. 2004 Mar;48(3):815-23 - PubMed
  20. Antimicrob Agents Chemother. 2001 Mar;45(3):696-700 - PubMed
  21. Lancet. 2003 Oct 4;362(9390):1142-51 - PubMed
  22. J Clin Pharmacol. 2004 Jun;44(6):590-8 - PubMed
  23. Ther Drug Monit. 1997 Aug;19(4):436-45 - PubMed
  24. Antimicrob Agents Chemother. 2004 Nov;48(11):4306-14 - PubMed
  25. Drug Metab Dispos. 2005 May;33(5):676-82 - PubMed
  26. Life Sci. 1993;52(1):29-34 - PubMed
  27. J Clin Pharmacol. 2005 Feb;45(2):227-33 - PubMed
  28. J Clin Pharmacol. 2007 Apr;47(4):461-70 - PubMed
  29. Clin Ther. 2002 Mar;24(3):351-77; discussion 329 - PubMed

Substances

MeSH terms

Publication Types